Immunization Program

TO: All CVP Providers
FROM: Mick Bolduc
Vaccine Coordinator–Connecticut Vaccine Program (CVP)
DATE: June 17, 2019

SUBJECT: Expansion of Rotavirus, Serogroup B Meningococcal and Influenza Vaccines

The primary purpose of this communication is to notify you of the expansion of state supplied rotavirus, serogroup B meningococcal and influenza vaccines.

**Expansion of Rotavirus Vaccine**
Rotavirus vaccine is routinely recommended for infants 6 weeks to 8 months of age. Beginning October 1, 2019 providers must begin to order rotavirus vaccine from the CVP for all patients including those with private insurance. The CVP will continue to provide both RotaTeq® and Rotarix® vaccines. As a reminder, RotaTeq® is a three dose schedule routinely administered at 2, 4, and 6 months of age, while Rotarix® is a two dose schedule routinely administered at 2 and 4 months of age.

**Expansion of Serogroup B Meningococcal Vaccine**
Serogroup B meningococcal vaccine is a category B recommendation from the Advisory Committee on Immunization Practices (ACIP), meaning the recommendation is based on individual clinical decision-making. The vaccine should be administered to certain individuals 10 years of age and older who are at increased risk of meningococcal disease including persons with persistent complement component deficiencies; persons who have anatomic or functional asplenia, including sickle cell disease; or anyone identified to be at risk because of a serogroup B meningococcal disease outbreak. Beginning October 1, 2019 providers must begin to order serogroup B meningococcal vaccine from the CVP for adolescents 16 through 18 years of age and any high risk individuals 10 through 18 years of age meeting the above conditions for all patients including those with private insurance. The CVP will continue to provide both Bexsero® and Trumenba® vaccines. Bexsero® is routinely administered in a two dose schedule with the second dose administered at least one month after the first dose. Trumenba® is routinely
administered in a two dose schedule with the second dose administered at least six months after
the first dose. In an outbreak situation or for persons at increased risk of meningococcal disease
three doses of Trumenba are needed at 0, 1-2, and 6 months.

**Expansion of Influenza vaccine**
Influenza vaccine is routinely recommended for all individuals 6 months of age and older.
*Beginning July 1, 2020 the CVP will begin providing influenza vaccine for all patients 6
months through 18 years of age including those with private insurance.* Since pre-booking of
flu doses has already taken place for the upcoming flu season, the CVP will not expand influenza
vaccine until the 2020-21 flu season.

As always if you have any questions, please feel free to contact me at (860) 509-7940.